Abstract:

ABSTRACT Hyperphosphatemia is very common in patients with chronic kidney disease (CKD) and end stage of renal disease (ESRD), and also is an independent factor for ESRD patients’ CVD events and death. Thus it is very important to control hyperphosphatemia. Phosphate binders are divided into calcium-based or non-calcium-based phosphate binders, such as calcium carbonate, calcium acetate, lanthanum carbonate, aluminum hydroxide and sevelamer. There is no difference among those phosphate binders in decreasing phosphate. Calcium-based phosphate binders is related to hypercalcemia, lower iPTH level and higher score of vascular calcification. In dialysis patients phosphate binder therapy can decrease the risk of all-cause mortality. Compared with calcium-based phosphate binders, non-calcium-based phosphate binders can decrease the all-cause mortality by 22% in dialysis patients. The aim of this paper is to review the new understanding of phosphate binders in patients with CKD and ESRD

Key words: chronic kidney disease, hyperphosphatemia, calcium-based phosphate binders, non-calcium-based phosphate binders